CochraneJGoeringPDurbinJButterillDDumasJWasylenkiD. Tertiary mental health services: II. Subpopulations and best practices for service delivery. Can J Psychiatry2000;45:185–90.
2.
van MinnenAHoogduinCBroekmanT. Hospital vs. outreach treatment of patients with mental retardation and psychiatric disorders: A controlled study. Acta Psychiatr Scand1997;95:515–22.
3.
XenitidisKHenryJRussellAWardAMurphyD. An inpatient treatment model for adults with mild intellectual disability and challenging behaviour. Journal of Intellectual Disability1999;43(2):128–34.
4.
McCrearyB. Educating physicians for contemporary responsibilities in the field of mental retardation. Can J Psychiatry1991;36:601–5.
5.
ClaghornJL. In: SadockBJSadockVA, editors. Kaplan and Sadock's comprehensive textbook of psychiatry. Volume 2. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p 2391.
6.
BenazziF. Mirtazepine withdrawal symptoms [letter]. Can J Psychiatry1998;43:525.
7.
StembachH. The serotonin syndrome. Am J Psychiatry1991;148:705–13.
8.
FisherAMcLeanAJPurcellPHerdsonPBDahlstromJECouteurDG. Focal necrotizing vasculitis with secondary myositis following fluoxetine administration. Aust N Z J Med1999;29:375–6.
9.
GillMLoVecchioFSeldonB. Serotonin syndrome in a child after a single dose of fluoxetine. Ann Emerg Med1999;33:457–9.
10.
OppenheimGBergmanJEnglishE. Failed appointments: A review. J Fam Prac1979;8:789–96.
11.
TepkaC. Attrition from an outpatient psychology clinic. Br J Med Psychol1986;59:181–6.
12.
MachariaSLeonG, Rowe B, and others. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA1992;267:1813–7.
13.
SwettCNoonesJ. Factors associated with premature termination from outpatient treatment. Hospital and Community Psychiatry1989;40:947–51.
14.
MillerWRRollnickS. Motivational interviewing: Preparing people to change addictive behaviour. New York: Guilford Press; 1991.
15.
DrakeRERosenbergSDMueserKT. Assessing substance use disorder in persons with severe mental illness. In: DrakeREMueserKT, editors. Dual diagnosis of major mental illness and substance abuse. Volume 2: Recent research and clinical implications. San Francisco: Jossey-Bass Publishers; 1996. p 3–18.
16.
FowlerILCarrVJCarterNTLewinTJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull1998;24(3):443–55.
17.
DixonLHaasGWeidenPJSweeneyJFrancesAJ. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry1991;148(2):224–230.
18.
JesteDVGladsjoJALacroJP. Medical comorbidity in schizophrenia. Schizophr Bull1996;22(3):413–30.
19.
MueserKTBellackASBlanchardJJ. Comorbidity of schizophrenia and substance abuse: Implications for treatment. J Consult Clin Psychol1992;60(6):845–56.
20.
OwenRRFischerEPBoothBMCuffelBJ. Medication non compliance and substance abuse among patients with schizophrenia. Psychiatric Services1996;47:853–58.
21.
WilkinsJN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull1997;23(2):215–28.
22.
DrakeREMercer-McFaddenCMueserKTMcHugoGJBondGR. Review of integrated mental health and substance abuse treatment for patients with dual diagnosis. Schizophr Bull1998;24(4):589–608.
23.
SirisSG. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull1990;16(1):111–22.
24.
GaravanJBrownSGervinMLaneALarkinCO'CallaghanE. Compliance with neuroleptic medication in outpatients with schizophrenia: Relationship to subjective response to neuroleptics: Attitudes to medication and insight. Comprehensive Psychiatry1998;39(4):215–9.
